Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Monoclonal Antibody Therapeutics

What Infusion Sites, Healthcare Providers, and Patients Need to Know

Monoclonal antibody therapeutics (mAb), including casirivimab/imdevimab and bamlanivimab, can be used to treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments mimic your immune system’s response to SARS-CoV-2 (the infection that causes COVID-19) and are available to  eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized. 

HHS/ASPR has purchased supplies of both COVID-19 monoclonal antibody therapeutic products and we are working with state and territorial health departments as well as national healthcare and medical organizations and associations to get casirivimab/imdevimab and bamlanivimab into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic.

Information for
Infusion Centers


Learn More button


Information for
Healthcare Providers


Learn More button


​​

Information for
Patients


Learn More button



  • This page last reviewed: March 08, 2021